in , , , ,

DoD Seeks to Establish Consortium for CBRN Countermeasures, Diagnostics

Joint Project Manager Medical Countermeasure Systems

The DoD’s Joint Project Manager for Medical Countermeasure Systems (JPM-MCS), part of the Joint Program Executive Office for Chemical and Biological Defense, is seeking to establish a consortium for advanced development efforts to support defense medical pharmaceutical and diagnostic requirements.

JPM-MCS provides U.S. military forces and the nation safe, effective, and innovative medical solutions to counter Chemical Biological Radiological and Nuclear (CBRN) threats. JPM-MCS accomplishes this mission through the development of products in three major areas:

  • Detection – systems and devices to identify CBRN agents and inform medical decisions
  • Prevention – prophylaxis, pretreatment, post-exposure prophylaxis
  • Treatment – therapeutics (post exposure, post symptomatic)

Chemical agents of concern fall under the broad categories of nerve, blister, blood, and pulmonary agents. Biological agents of concern include bacterial, toxin and viral threat agents. Radiation threats result from nuclear detonations, nuclear accidents, or spread of radioactive materials through improvised radioactive explosive devices or other means of radioactive particulate dispersion, either intentional or accidental.

The effort seeks interested parties that are willing to join and/or establish an Other Transaction Agreement (OTA) consortium to provide collective, diverse expertise in support of the JPM-MCS mission. Input is sought on the following:

  • Under what conditions/circumstances would industry participate in an OTA consortium?
  • What barriers does industry see in working with the DoD in an OTA consortium strategy? (legal, intellectual property rights, royalties, inclusion of DoD Advance Development & Manufacturing Capability, membership rules, FAR applicability).
  • What incentives would industry like to see included as part of an OTA consortium strategy? (number and value of projects to be awarded within the consortium, time frame for the awards to be made and work to be accomplished, limited liability).

An industry day is planned to occur June 15, 2015 in Philadelphia, PA. This event will provide industry and academia the opportunity to obtain further details and engage in discussion with government program managers.

The industry day will also provide another venue for discussion of the barriers and incentives associated with the establishment and use of an OTA consortium to meet JPM-MCS mission requirements.

Further details are available via Solicitation Number: W15QKN15Z8608.

Contract Award to GSK for Leishmaniasis Drug

908 Devices Selected for Next-Gen Chemical Detection Program